Journal Article

Bacteriophage Therapy: Exploiting Smaller Fleas

Stan Deresinski

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 48, issue 8, pages 1096-1101
Published in print April 2009 | ISSN: 1058-4838
Published online April 2009 | e-ISSN: 1537-6591 | DOI:
Bacteriophage Therapy: Exploiting Smaller Fleas

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Although bacteriophages have been used for the treatment of patients with bacterial infections in some regions of the world for >9 decades, adequate clinical trials of the safety and efficacy of the treatment have not been reported. The increasing problem of antibiotic resistance has, however, rekindled interest in this approach to therapy. Although potentially significant obstacles to systemic administration of phages exist, topical and oral administration of phages and/or phage products, such as lysins, are feasible in the short term. In addition to exploitation of the effects of native phages and phage products, bioengineering of phages will allow directed specificity and their use as delivery systems for antimicrobial and antivirulence molecules. This brief overview of the history and status of phage therapy, along with speculation about its future, provides a background for understanding of this imminent therapeutic modality.

Journal Article.  4524 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.